In 2009, Tyner et al. [1] identified LMTK3 as a potential target in chronic neutrophilic leukaemia (CNL) since patient-derived CNL cells carrying the JAK2 V617F mutation were sensitive to LMTK3 silencing. Here, LMTK3 is linked to chronic neutrophilic leukemia.